Navigation Links
Rheumatoid Arthritis Patient Share of Actemra Projected to Exceed Patient Share of Cimzia and Simponi Among the Medicare Population
Date:11/3/2010

EXTON, Pa., Nov. 3, 2010 /PRNewswire/ -- Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010.  This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.

Despite the availability of newer TNF-alpha inhibitors, the TNF refractory market still remains relatively large. As many as one-fourth of first-time biologic users ultimately require a switch to another biologic agent due to poor response or waning efficacy of TNF-alpha inhibitors. However, the newer TNF-alpha inhibitors and biologic agents with alternative mechanisms of action are still perceived as less efficacious and less safe compared to the established TNF-alpha inhibitors.

The patient market share for the newest biologic agent, Genentech-Roche's Actemra (launched in January 2010), is currently estimated to be less than 5 percent among biologic-treated, rheumatoid arthritis (RA) patients.  However, according to surveyed rheumatologists' projections, the patient share of Actemra among the Medicare RA population is projected to exceed the patient share estimates of UCB's Cimzia and Centocor Ortho Biotech's Simponi in the next six months.  Furthermore, the patient share of Actemra among rheumatologists with in-office-infusion capability is projected to increase by more than 50 percent in the next six months.  

Amgen/Pfizer's Enbrel and Abbott Labs' Humira are currently the preferred first- and second-line biologic agents, respectively, among surveyed rheumatologists for the treatment of RA. However, almost one-fifth of rheumatologists cited decreased usage of both Enbrel an
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in This Drug Class
2. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
3. Deadline Approaching for UCB Rheumatoid Arthritis Family Scholarship
4. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
5. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
8. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
9. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... May 15, 2012  Cardium Therapeutics (NYSE Amex: ... UK-based Angel Biomedical Limited, a subsidiary of Angel ... contract manufacturer, covering the manufacture of formulated collagen ... for marketing by the U.S. Food and Drug ...
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , ... treatment and diagnosis of cancer, today announced that ... a U.S. multi-center Phase 1b dose-escalation trial of ... cancer patients with advanced solid tumors.  The first ...
Cached Medicine Technology:Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 2Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 3Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 4Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 5Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 6Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 2Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 3Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 4
(Date:4/20/2014)... PHILADELPHIA Researchers may have identified key genes linked ... pain than others, according to a study released today ... Neurology,s 66th Annual Meeting in Philadelphia, April 26 to ... significant because it provides an objective way to understand ... levels," said study author Tobore Onojjighofia, MD, MPH, with ...
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
Breaking Medicine News(10 mins):Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2
... 6, 2010 (Philadelphia, PA) -- Src (short for sarcoma) ... in many cancer tumors, including medulloblastoma, the most common ... most promising targets for cancer therapy. A recent ... be effective in interfering with the cell cycle and ...
... Jens Bangsbo from the Department of Exercise and Sports ... intervention studies involving both men, women and children, who ... results from the studies are so remarkable that the ... are publishing a special edition issue entitled "Football ...
... wind up in ER during major U.S. holidays, researchers find, ... are injured during the holidays, it,s not too many chocolate ... damage, a new study shows. , Rather, it is the ... fall prey to, the researchers from Nationwide Children,s Hospital in ...
... ... Superfruit Companies , ... (Vocus) -- Tahitian Noni International (TNI) announced a new quarter of a million ... other product in the industry will measure up to Tahitian Noni Bioactive Beverages., , , ...
... ... Excellence in Financial Journalism Award from the New York State Society of Certified Public Accountants ... New York, NY ... CFO magazine , won an Excellence in Financial Journalism Award from the New York ...
... ... PeopleStreme Human Capital has announced a collaboration with SkillSoft ... its clients.,We are thrilled to collaborate with SkillSoft to provide SkillSoft’s ... is a clear leader in the provision of our technology enabled ...
Cached Medicine News:Health News:New pyrimidine compounds may lead to improved treatments for childhood brain cancer 2Health News:Scientists: Soccer improves health, fitness and social abilities 2Health News:Scientists: Soccer improves health, fitness and social abilities 3Health News:Scientists: Soccer improves health, fitness and social abilities 4Health News:Most Holiday Injuries to Kids Spurred by Everyday Mishaps 2Health News:Quarter of a Million Dollar Superfruit Challenge Announced 2Health News:CFO magazine Wins Excellence in Financial Journalism Award 2Health News:PeopleStreme Collaborates with SkillSoft for Learning Management Content 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: